To view the multimedia assets associated with this release, please click: http://multivu.prnewswire.com/mnr/icad/45942/
(Photo: http://photos.prnewswire.com/prnh/20100831/MM57178 )
(Photo: http://www.newscom.com/cgi-bin/prnh/20100831/MM57178 )
"I am honored to ring the NASDAQ closing bell, and pleased to be provided the opportunity to raise awareness about prostate cancer," said Ken Ferry, President and CEO of iCAD. "Early detection is a first-line defense in the journey towards beating cancer, and iCAD is proud to provide advanced image analysis solutions that help clinicians make a more accurate diagnosis in conjunction with available screening tools."
One in six men will be affected by prostate cancer over the course of their lifetime, and MRI plays an important role in the accurate diagnosis and treatment decisions facing prostate cancer patients. VividLook®, iCAD's Prostate MRI advanced image analysis solution, helps radiologists determine malignant from benign tissues and pinpoint tumor location and size. Additionally, VividLook provides enhanced diagnostic information by utilizing data from all available time points, creating colorized image maps based on signal changes defined by tumor physiology. With advanced diagnostic imaging tools, physicians can more accurately determine the extent of the prostate cancer, minimize a patient's exposure to unnecessary and painful biopsies and provide more detailed information for men who choose active surveillance versus surgical or therapeutic treatment.
About iCAD, Inc.
iCAD, Inc. is an industry-leading provider of advanced image analysis and workflow solutions that enable healthcare professionals to better serve patients by identifying pathologies and pinpointing cancer earlier. iCAD offers a comprehensive range of high-performance, upgradeable Computer-Aided Detection (CAD) systems and workflow solutions for mammography (film-based, digital radiography and computed radiography), Magnetic Resonance Imaging (MRI) and Computed Tomography (CT). Since receiving FDA approval for the Company's first breast cancer detection product in 2002, more than 3,800 iCAD systems have been placed in healthcare practices worldwide. iCAD's solutions aid in the early detection of the most prevalent cancers including breast, prostate, colon and in the future lung cancer. For more information, call (877) iCADnow or visit www.icadmed.com.
"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995:
Certain statements contained in this News Release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited to, the risks of uncertainty of patent protection, the impact of supply and manufacturing constraints or difficulties, product market acceptance, possible technological obsolescence, increased competition, customer concentration and other risks detailed in the Company's filings with the Securities and Exchange Commission. The words "believe", "demonstrate", "intend", "expect", "estimate", "anticipate", "likely", and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release.
SOURCE iCAD Inc.
